Patent US4753958A successfully refreshed from Google Patents.
US4753958A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Photochemotherapy of epithelial diseases with derivatives of hematoporphyrins
Assignee: University of California
•
Filing: 1986-06-25
•
Granted: 1988-06-28
•
Expires: 2006-06-25
Abstract
Abstract Topical compositions for the treatment of an epithelial disease, such as psoriasis and cervical displasia, containing phototoxic derivatives of hematoporphyrin and methods for treating epithelial diseases with phototoxic derivatives of hematoporphyrin.
Inventors
- 👤 Gerald D. Weinstein
- 👤 Jerry L. McCullough
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 15:50
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0014; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K47/00; A61K47/06; A61K47/22
Claims Analysis
Total Claims: 47
Claim 1
Independent Claim
57 words
A composition for topical application in the photochemotherapy of an epithelial disease comprising a topical carrier and a therapeutically effective amount of the component of Hematoporphyrin Derivative that is phototoxic to psoriatic tissue, said topical carrier selected from the group consisting of a cream, an ointment, a gel, a lotion and a solution containing N-methylpyrollidone or Azone.
Claim 2
Dependent Claim
57 words
A composition for topical application in the photochemotherapy of an epithelial disease comprising a topical carrier and a therapeutically effective amount of the component of Hematoporphyrin Derivative that is phototoxic to psoriatic tissue, said topical carrier selected from the group consisting of a cream, an ointment, a gel, a lotion and a solution containing N-methylpyrollidone or Azone.
Claim 3
Dependent Claim
14 words
The composition of claim 1 wherein said component of Hematoporphyrin Derivative is dihematoporphyrin ether.
Claim 4
Dependent Claim
20 words
The composition of claim 2 wherein the concentration of dihematoporphyrin ether is from about 0.1% to about 10% by weight.
Claim 5
Dependent Claim
20 words
The composition of claim 3 wherein the concentration of dihematoporphyrin ether is from about 0.5% to about 5% by weight.
Claim 6
Dependent Claim
20 words
The composition of claim 4 wherein the concentration of dihematoporphyrin ether is from about 0.5% to about 1.5% by weight.
Claim 7
Dependent Claim
11 words
The composition of claim 2 wherein said topical carrier contains 1-dodecyl-azacycloheptan-2-one.
Claim 8
Dependent Claim
25 words
The composition of claim 4 wherein said topical carrier contains 1-dodecyl-azacycloheptan-2-one at a concentration from about 0.5% to about 10% by weight of said composition.
Claim 9
Dependent Claim
22 words
The composition of claim 7 wherein said concentration of 1-dodecyl-azacycloheptan-2-one is from about 3% to about 5% by weight of said composition.
Claim 10
Dependent Claim
22 words
The composition of claim 5 wherein said topical carrier contains from about 3% to about 5% 1-dodecyl-azacycloheptan-2-one by weight of said composition.
Claim 11
Dependent Claim
15 words
The composition of claim 2 wherein said topical carrier is a viscous topical medicament carrier.
Claim 12
Dependent Claim
15 words
The composition of claim 3 wherein said topical carrier is a viscous topical medicament carrier.
Claim 13
Dependent Claim
15 words
The composition of claim 4 wherein said topical carrier is a viscous topical medicament carrier.
Claim 14
Dependent Claim
15 words
The composition of claim 5 wherein said topical carrier is a viscous topical medicament carrier.
Claim 15
Dependent Claim
15 words
The composition of claim 7 wherein said topical carrier is a viscous topical medicament carrier.
Claim 16
Dependent Claim
48 words
A composition for topical application in the photochemotherapy of hyperproliferative epithelial disease comprising a topical carrier and a therapeutically effective amount of Hematoporphyrin Derivative, said topical carrier selected from the group consisting of a cream, an ointment, a gel, a lotion and a solution containing N-methylpyrollidone or Azone.
Claim 17
Dependent Claim
48 words
A composition for topical application in the photochemotherapy of hyperproliferative epithelial disease comprising a topical carrier and a therapeutically effective amount of Hematoporphyrin Derivative, said topical carrier selected from the group consisting of a cream, an ointment, a gel, a lotion and a solution containing N-methylpyrollidone or Azone.
Claim 18
Dependent Claim
20 words
The composition of claim 15 wherein the concentration of Hematoporphyrin Derivative is from about 0.1% to about 10% by weight.
Claim 19
Dependent Claim
20 words
The composition of claim 16 wherein the concentration of Hematoporphyrin Derivative is from about 0.5% to about 5% by weight.
Claim 20
Dependent Claim
20 words
The composition of claim 17 wherein the concentration of Hematoporphyrin Derivative is from about 0.5% to about 1.5% by weight.
Claim 21
Dependent Claim
11 words
The composition of claim 15 wherein said topical carrier contains 1-dodecyl-azacycloheptan-2-one.
Claim 22
Dependent Claim
11 words
The composition of claim 16 wherein said topical carrier contains 1-dodecyl-azacycloheptan-2-one.
Claim 23
Dependent Claim
15 words
The composition of claim 15 wherein said topical carrier is a viscous topical medicament carrier.
Claim 24
Dependent Claim
15 words
The composition of claim 16 wherein said topical carrier is a viscous topical medicament carrier.
Claim 25
Dependent Claim
15 words
The composition of claim 19 wherein said topical carrier is a viscous topical medicament carrier.
Claim 26
Independent Claim
69 words
A method of photochemotherapy for hyperproliferative epithelial diseases comprising: (a) treating an area of tissue afflicted by a proliferative epithelial disease by applying topically or intradermally a therapeutically effective amount of Hematoporphyrin Derivative or the component of Hematoporphyrin Derivative that is phototoxic to psoriatic tissue; and (b) exposing said treated tissue to radiation that photoactivates said component of Hematoporphyrin Derivative to produce a cytotoxic response in said afflicted tissue.
Claim 27
Independent Claim
69 words
A method of photochemotherapy for hyperproliferative epithelial diseases comprising: (a) treating an area of tissue afflicted by a proliferative epithelial disease by applying topically or intradermally a therapeutically effective amount of Hematoporphyrin Derivative or the component of Hematoporphyrin Derivative that is phototoxic to psoriatic tissue; and (b) exposing said treated tissue to radiation that photoactivates said component of Hematoporphyrin Derivative to produce a cytotoxic response in said afflicted tissue.
Claim 28
Dependent Claim
16 words
The method of claim 24 wherein step (a) comprises treating said afflicted tissue with dihematoporphyrin ether.
Claim 29
Dependent Claim
16 words
The method of claim 24 wherein step (a) comprises treating said afflicted tissue with Hematoporphyrin Derivative.
Claim 30
Dependent Claim
22 words
The method of claim 25 wherein said radiation is selected from the group consisting of the visible spectrum and the ultraviolet spectrum.
Claim 31
Dependent Claim
19 words
The method of claim 25 wherein said radiation is selected from the group consisting of red light and UVA.
Claim 32
Dependent Claim
25 words
The method of claim 25 wherein said dihematoporphyrin ether is applied to said afflicted tissue topically in a composition comprising a viscous topical medicament carrier.
Claim 33
Dependent Claim
23 words
The method of claim 29 wherein the concentration of dihematoporphyrin ether in said composition is from about 0.1% to about 10% by weight.
Claim 34
Dependent Claim
23 words
The method of claim 29 wherein the concentration of dihematoporphyrin ether in said composition is from about 0.5% to about 5% by weight.
Claim 35
Dependent Claim
21 words
The method of claim 25 wherein said dihematoporphyrin ether is applied topically in the presence of a skin penetration enhancing agent.
Claim 36
Dependent Claim
13 words
The method of claim 32 wherein said skin penetration enhancing agent is 1-dodecyl-azacycloheptan-2-one.
Claim 37
Dependent Claim
15 words
The method of claim 29 wherein said topical carrier comprises a skin penetration enhancing agent.
Claim 38
Dependent Claim
11 words
The method of claim 29 wherein said composition further comprises 1-dodecyl-azacycloheptan-2-one.
Claim 39
Dependent Claim
19 words
The method of claim 31 wherein said composition further comprises from about 1% to about 4% 1-dodecyl-azacycloheptan-2-one by weight.
Claim 40
Dependent Claim
21 words
The method of claim 24 wherein said hyperproliferative epithelial disease is selected from the group consisting of psoriasis and cervical displasia.
Claim 41
Dependent Claim
21 words
The method of claim 27 wherein said hyperproliferative epithelial disease is selected from the group consisting of psoriasis and cervical displasia.
Claim 42
Dependent Claim
21 words
The method of claim 31 wherein said hyperproliferative epithelial disease is selected from the group consisting of psoriasis and cervical displasia.
Claim 43
Dependent Claim
21 words
The method of claim 35 wherein said hyperproliferative epithelial disease is selected from the group consisting of psoriasis and cervical displasia.
Claim 44
Dependent Claim
14 words
The method of claim 24 wherein said component of Hematoporphyrin Derivative is applied topically.
Claim 45
Dependent Claim
13 words
The method claim 41 wherein said component of Hematoporphyrin Derivative is dihematoporphyrin ether.
Claim 46
Dependent Claim
11 words
The method of claim 41 wherein Hematoporphyrin Derivative is applied topically.
Claim 47
Dependent Claim
21 words
The method of claim 41 wherein said hyperproliferative epithelial disease is selected from the group consisting of psoriasis and cervical dysplasia.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-06-28 | 1991-12-28 | 1992-06-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-06-28 | 1995-12-28 | 1996-06-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-06-28 | 1999-12-28 | 2000-06-28 | $7700.00 | Window Closed / Lapsed |